Sequential therapies for advanced urothelial cancer: Hope meets new challenges

Daniel Herchenhorn1, Vinicius Freire2, Thamires Oliveira2

  • 1Grupo de Oncologia D'Or, Instituto D'Or de Ensino e Pesquisa, Brazil; Latin America Cooperative Oncology Group - LACOG, Brazil.

Insights

Recent advances in urothelial carcinoma (UC) treatment include new immunotherapies and targeted agents like anti-FGFR and anti-nectin-4 inhibitors. This review guides oncologists on integrating these novel therapies for advanced UC.

Area of Science:

  • Oncology
  • Urothelial Carcinoma Research
  • Medical Treatment Advancements

Background:

  • Advanced urothelial carcinoma (UC) treatment has seen significant evolution.
  • The last three years introduced immune check-point inhibitors for first and second-line therapies.

Purpose of the Study:

  • To review new classes of agents for advanced UC.
  • To explore the integration of novel therapies into clinical practice.
  • To guide oncologists on treatment sequencing for metastatic UC.

Main Methods:

  • Review of recent clinical trial data.
  • Analysis of preliminary results from randomized phase 3 trials.
  • Exploration of novel therapeutic agents including anti-FGFR and anti-nectin-4 inhibitors.

Main Results:

  • Approval of anti-FGFR and anti-nectin-4 inhibitors for refractory disease.
  • Positive preliminary results from randomized trials combining chemotherapy and immunotherapy.
  • Emergence of maintenance immunotherapy strategies post-chemotherapy induction.

Conclusions:

  • A new treatment paradigm for metastatic urothelial carcinoma has been established.
  • Novel agents and treatment combinations are reshaping clinical practice.
  • Evidence-based guidance is provided for sequencing advanced UC therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K